Recipharm further extends the acceptance period for the offer to acquire Consort Medical and updates on level of acceptance

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES.

Recipharm Holdings Limited ("Recipharm") is issuing a correction to an announcement it made on 22 January 2020 (the "Announcement") in respect of its purchase of ordinary shares in Consort Medical plc ("Consort").

In the Announcement it was stated that Recipharm had acquired 4,881,437 Consort Shares, representing 9.9 per cent. of the existing issued share capital of Consort, at 1,010 pence per share and a further 118,563 Consort Shares, representing 0.2 per cent. of the existing issued share capital of Consort at 1,000 pence per share (the "Share Acquisition").

The correct numbers in respect of the Share Acquisition are 4,815,000 Consort Shares, representing 9.8 per cent. of the existing issued share capital of Consort, purchased at 1,010 pence per share and a further 185,000 Consort Shares, representing 0.4 per cent. of the existing issued share capital of Consort, purchased at 1,000 pence per share. The total number of Consort Shares purchased by Recipharm pursuant to the Share Acquisition remains unchanged at 5,000,000, representing 10.1 per cent. of the existing share capital of Consort.

Recipharm’s Offer remains open for acceptances until 1.00 pm (London time) on 4 February 2020, and Consort Shareholders are encouraged to submit their acceptances without delay.

Unless otherwise stated, the terms used in this announcement have the same meanings as given to them in the offer document published by Recipharm on 6 December 2019 in respect of Recipharm's recommended cash offer for the entire issued and to be issued share capital of Consort.
 

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com

 

IMPORTANT INFORMATION

This publication is neither an offer to buy or sell nor an invitation to tender or offer to buy or sell shares.

The Offer will be implemented solely by means of the Offer Document and, in respect of Consort Shares held in certificated form, the Form of Acceptance accompanying the Offer Document, which will contain the full terms and conditions of the Offer including details of how to accept the Offer. Any approval, acceptance, decision or other response to the Offer should be made only on the basis of the information in the Offer Document and, in respect of Consort Shares held in certificated form, the Form of Acceptance. Consort Shareholders are strongly advised to read the formal documentation in relation to the Offer and each Consort Shareholder is urged to consult its independent professional adviser immediately regarding the tax consequences to it (or its beneficial owners) of the Offer.

This press release is not being published in or distributed to or into and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country. Persons who receive this press release (including, without limitation, nominees, trustees and custodians) and are subject to the law of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction.

To the extent this press release contains forward-looking statements, such statements do not represent facts and are characterized by the words "will", "expect", "believe", "estimate", "intend", "aim", "assume" or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of Recipharm. Such forward-looking statements are based on current plans, estimates and forecasts which Recipharm has made to the best of its knowledge, but which do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and usually cannot be influenced by Recipharm. It should be kept in mind that the actual events or consequences may differ materially from those contained in or expressed by such forward-looking statements.

Publication on a website

A copy of this announcement will be made available, subject to certain restrictions relating to persons resident in restricted jurisdictions, on Recipharm's website at www.recipharm.com/investor-relations promptly and in any event by no later than 12 noon (London time) on the business day following this announcement. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Recipharm AB (publ), Org. nr 556498-8425
Adress Box 603, 101 32 Stockholm, Sverige, Telefon 46 8 602 52 00
www.recipharm.com

Did you like this article?